Equity
Total Liabilities & Equity
Alnylam Pharmaceuticals Total Liabilities & Equity increased by 3.3% to $5.13B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.7%, from $4.21B to $5.13B. Over 5 years (FY 2020 to FY 2025), Total Liabilities & Equity shows an upward trend with a 7.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
An increase typically reflects overall balance sheet growth or expansion of the company's asset base, while a decrease may indicate divestitures or debt repayment.
Detailed definition
This represents the sum of all claims against a company's assets, combining obligations to external creditors and the re...
Peer comparison
This is a standard accounting identity used across all industries to verify that assets equal the sum of liabilities and equity.
Metric ID:
total_liabilities_and_equityHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.51B | $3.47B | $3.64B | $3.43B | $3.33B | $3.54B | $3.55B | $3.39B | $3.40B | $3.84B | $3.83B | $3.82B | $4.01B | $4.21B | $4.24B | $4.21B | $4.57B | $4.85B | $4.97B | $5.13B |
| QoQ Change | — | -1.1% | +4.9% | -5.8% | -3.0% | +6.2% | +0.3% | -4.4% | +0.3% | +12.8% | -0.2% | -0.1% | +4.8% | +4.9% | +0.8% | -0.6% | +8.4% | +6.3% | +2.4% | +3.3% |
| YoY Change | — | — | — | — | -5.1% | +1.8% | -2.7% | -1.2% | +2.2% | +8.6% | +8.0% | +12.7% | +17.8% | +9.5% | +10.7% | +10.2% | +13.9% | +15.4% | +17.1% | +21.7% |
Range$3.33B – $5.13B
CAGR+8.3%
Avg YoY Growth+8.8%
Median YoY Growth+9.9%
Current Streak4 quarters growth
Total Liabilities & Equity at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's total liabilities & equity?
- Alnylam Pharmaceuticals (ALNY) reported total liabilities & equity of $5.13B in Q1 2026.
- How has Alnylam Pharmaceuticals's total liabilities & equity changed year-over-year?
- Alnylam Pharmaceuticals's total liabilities & equity increased by 21.7% year-over-year, from $4.21B to $5.13B.
- What is the long-term trend for Alnylam Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's total liabilities & equity has grown at a 7.8% compound annual growth rate (CAGR), from $3.41B to $4.97B.
- What does total liabilities & equity mean?
- The total amount of money a company owes to others plus the value owned by its shareholders.